Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
|Articles|February 21, 2012
To Ease Shortage, F.D.A. Lets 2 Cancer Drugs Be Imported
Advertisement
cancer
Dire shortages of two critical drugs — shortfalls that have threatened the lives and care of thousands of cancer patients — should be resolved within weeks, federal drug officials said.
The two drugs are doxorubicin and methotrexate, and in both cases supplies in the United States are being bolstered by shipments from abroad.
“We’re not out of the woods,” said Dr. Sandra L. Kweder of the Food and Drug Administration’s drug center. “But these two particular shortages have been very, very upsetting to patients and to us.”
Read the full story:
Source: The New York Times
Advertisement
Related to this article
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5